Acknowledgement
This study was supported by a grant from the National R & D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (No. 1520140).
References
- Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst 2017;109(9):djx030.
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-249. https://doi.org/10.3322/caac.20006
- Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61(6):1079-1092. https://doi.org/10.1016/j.eururo.2012.02.054
- Won YJ, Jung KW, Oh CM, Park EH, Kong HJ, Lee DH, et al. Geographical variations and trends in major cancer incidences throughout Korea during 1999-2013. Cancer Res Treat 2018;50(4):1281-1293. https://doi.org/10.4143/crt.2017.411
- Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol 2018;25(6):524-531. https://doi.org/10.1111/iju.13593
- Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, et al, Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer 2018;124(13):2785-2800. https://doi.org/10.1002/cncr.31551
- Jung KW, Won YJ, Kong HJ, Lee ES; Community of Population-Based Regional Cancer Registries. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. Cancer Res Treat 2018;50(2):303-316. https://doi.org/10.4143/crt.2018.143
- Lee KS, Chang HS, Lee SM, Park EC. Economic burden of cancer in Korea during 2000-2010. Cancer Res Treat 2015;47(3):387-398. https://doi.org/10.4143/crt.2014.001
- Lee YJ, Lee JW, Park J, Seo SI, Chung JI, Yoo TK, et al. Nationwide incidence and treatment pattern of benign prostatic hyperplasia in Korea. Investig Clin Urol 2016;57(6):424-430. https://doi.org/10.4111/icu.2016.57.6.424
- Robert G, De La Taille A, Descazeaud A. Epidemiology of benign prostatic hyperplasia. Prog Urol 2018;28(15):803-812 (French). https://doi.org/10.1016/j.purol.2018.08.005
- Park HJ, Won JE, Sorsaburu S, Rivera PD, Lee SW. Urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and LUTS/BPH with erectile dysfunction in Asian men: a systematic review focusing on tadalafil. World J Mens Health 2013;31(3):193-207. https://doi.org/10.5534/wjmh.2013.31.3.193
- Roehrborn CG, Egan KB, Miner MM, Ni X, Wong DG, Rosen RC. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment. BJU Int 2016;118(1):153-160. https://doi.org/10.1111/bju.13406
- Glina S, Santana AW, Azank F, Mello LF, Moreira ED Jr. Lower urinary tract symptoms and erectile dysfunction are highly prevalent in ageing men. BJU Int 2006;97(4):763-765. https://doi.org/10.1111/j.1464-410X.2005.06008.x
- Morant S, Bloomfield G, Vats V, Chapple C. Increased sexual dysfunction in men with storage and voiding lower urinary tract symptoms. J Sex Med 2009;6(4):1103-1110. https://doi.org/10.1111/j.1743-6109.2008.01120.x
- Rosen RC, Wei JT, Althof SE, Seftel AD, Miner M, Perelman MA, et al. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry. Urology 2009;73(3):562-566. https://doi.org/10.1016/j.urology.2008.05.034
- Dolan P, Gudex C, Kind P, Williams A. Valuing health states: a comparison of methods. J Health Econ 1996;15(2):209-231. https://doi.org/10.1016/0167-6296(95)00038-0
- Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull 2010;96:5-21. https://doi.org/10.1093/bmb/ldq033
- Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005, p. 147-173.
- Torrance GW. Social preferences for health states: an empirical evaluation of three measurement techniques. Socioecon Plann Sci 1976;10(3):129-136. https://doi.org/10.1016/0038-0121(76)90036-7
- Wee HL, Li SC, Xie F, Zhang XH, Luo N, Feeny D, et al. Validity, feasibility and acceptability of time trade-off and standard gamble assessments in health valuation studies: a study in a multiethnic Asian population in Singapore. Value Health 2008;11 Suppl 1:S3-S10. https://doi.org/10.1111/j.1524-4733.2008.00361.x
- Kim SH, Lee SI, Jo MW. Feasibility, comparability, and reliability of the standard gamble compared with the rating scale and time trade-off techniques in Korean population. Qual Life Res 2017;26(12):3387-3397. https://doi.org/10.1007/s11136-017-1676-4
- Bleichrodt H, Johannesson M. Standard gamble, time trade-off and rating scale: experimental results on the ranking properties of QALYs. J Health Econ 1997;16(2):155-175. https://doi.org/10.1016/S0167-6296(96)00509-7
- Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986;5(1):1-30. https://doi.org/10.1016/0167-6296(86)90020-2
- Torrance GW, Feeny D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making 2001;21(4):329-334. https://doi.org/10.1177/0272989X0102100408
- Bremner KE, Chong CA, Tomlinson G, Alibhai SM, Krahn MD. A review and meta-analysis of prostate cancer utilities. Med Decis Making 2007;27(3):288-298. https://doi.org/10.1177/0272989X07300604
- Norman R, Cronin P, Viney R, King M, Street D, Ratcliffe J. International comparisons in valuing EQ-5D health states: a review and analysis. Value Health 2009;12(8):1194-1200. https://doi.org/10.1111/j.1524-4733.2009.00581.x
- Wittenberg E, Halpern E, Divi N, Prosser LA, Araki SS, Weeks JC. The effect of age, race and gender on preference scores for hypothetical health states. Qual Life Res 2006;15(4):645-653. https://doi.org/10.1007/s11136-005-3514-3
- Kim Y, Hwang JS, Ahn J, Lee SM, Lee YJ, Shin S. Utilities for prostate cancer by cancer stage and treatment step in Korea. Korean J Health Econ Policy 2013;19(2):1-20 (Korean).
- Kim SH, Jo MW, Ock M, Lee HJ, Lee JW. Estimation of health state utilities in breast cancer. Patient Prefer Adherence 2017;11:531-536. https://doi.org/10.2147/PPA.S129856
- Claxton K, Walker S, Palmer S, Sculpher M. Appropriate perspectives for health care decisions; 2010 [cited 2021 Jul 1]. Available from: https://www.york.ac.uk/media/che/documents/papers/researchpapers/rp54_appropriate_perspectives_for_health_care_decisions.pdf.
- Jo MW, Kwon DS, Kim SH, Kil SR, Lee SI. Validity and reliability of Korean EQ-5D valuation study using a computer-assisted standard gamble method. Korean J Health Promot 2010;10(3):105-112 (Korean).
- Krahn M, Ritvo P, Irvine J, Tomlinson G, Bremner KE, Bezjak A, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care 2003;41(1):153-164. https://doi.org/10.1097/00005650-200301000-00017
- Gries KS, Regier DA, Ramsey SD, Patrick DL. Utility estimates of disease-specific health states in prostate cancer from three different perspectives. Appl Health Econ Health Policy 2017;15(3):375-384. https://doi.org/10.1007/s40258-016-0282-x
- Torvinen S, Farkkila N, Sintonen H, Saarto T, Roine RP, Taari K. Health-related quality of life in prostate cancer. Acta Oncol 2013;52(6):1094-1101. https://doi.org/10.3109/0284186X.2012.760848
- Bergius S, Torvinen S, Muhonen T, Roine RP, Sintonen H, Taari K. Health-related quality of life among prostate cancer patients: real-life situation at the beginning of treatment. Scand J Urol 2017;51(1):13-19. https://doi.org/10.1080/21681805.2016.1247293
- Krahn MD, Bremner KE, Tomlinson G, Naglie G. Utility and health-related quality of life in prostate cancer patients 12 months after radical prostatectomy or radiation therapy. Prostate Cancer Prostatic Dis 2009;12(4):361-368. https://doi.org/10.1038/pcan.2009.32
- Smith KJ, Roberts MS. Quality-of-life utility values for erectile function and sildenafil treatment. Clin Drug Investig 2005;25(2):99-105. https://doi.org/10.2165/00044011-200525020-00002
- Postulart D, Adang EM. Response shift and adaptation in chronically ill patients. Med Decis Making 2000;20(2):186-193. https://doi.org/10.1177/0272989X0002000204
- Pickard AS, De Leon MC, Kohlmann T, Cella D, Rosenbloom S. Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care 2007;45(3):259-263. https://doi.org/10.1097/01.mlr.0000254515.63841.81
- Morimoto T, Fukui T. Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals. J Epidemiol 2002;12(2):160-178. https://doi.org/10.2188/jea.12.160